Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 77Unknown 33Terminated 30Recruiting 12Active not recruiting 8Withdrawn 4Not yet recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Rare Tumour 1Lung Diseases, Interstitial 1Hodgkin Disease 1Her2-negative Metastatic Breast Cancer 1HER2-positive Advanced Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 16pertuzumab 14Capecitabine 14Docetaxel 12pyrotinib 11Cyclophosphamide 11Standard of Care 10Paclitaxel 10Letrozole 10trastuzumab deruxtecan 9Radiotherapy 9Carboplatin 9Fulvestrant 8Drug Therapy 8sacituzumab govitecan 7dalpiciclib 7exemestane 6eribulin 6Tamoxifen 6Epirubicin 6Anastrozole 6pembrolizumab 5palbociclib 5abemaciclib 5Surveys and Questionnaires 5Neoadjuvant Therapy 5Aromatase Inhibitors 5camrelizumab 4Sentinel Lymph Node Biopsy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Breast Neoplasms × Vinorelbine × Clear all
NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3 Not yet recruiting
400 enrolled
Breast

Breast Neoplasms, Recurrence

NCT06229067 2024-01-29

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
182 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04922008 2021-06-10

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)

Fudan University

Phase 2 Not yet recruiting
356 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡